<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Li Y</submitter><funding>National Natural Science Foundation of China</funding><pagination>49</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10854045</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>22(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>TMPRSS2-ERG (T2E) fusion is highly related to aggressive clinical features in prostate cancer (PC), which guides individual therapy. However, current fusion prediction tools lacked enough accuracy and biomarkers were unable to be applied to individuals across different platforms due to their quantitative nature. This study aims to identify a transcriptome signature to detect the T2E fusion status of PC at the individual level.&lt;h4>Methods&lt;/h4>Based on 272 high-throughput mRNA expression profiles from the Sboner dataset, we developed a rank-based algorithm to identify a qualitative signature to detect T2E fusion in PC. The signature was validated in 1223 samples from three external datasets (Setlur, Clarissa, and TCGA).&lt;h4>Results&lt;/h4>A signature, composed of five mRNAs co</pubmed_abstract><journal>World journal of surgical oncology</journal><pubmed_title>Individualized detection of TMPRSS2-ERG fusion status in prostate cancer: a rank-based qualitative transcriptome signature.</pubmed_title><pmcid>PMC10854045</pmcid><funding_grant_id>32270710</funding_grant_id><pubmed_authors>Li Y</pubmed_authors><pubmed_authors>Liu K</pubmed_authors><pubmed_authors>Xia J</pubmed_authors><pubmed_authors>Huang DS</pubmed_authors><pubmed_authors>Gu Y</pubmed_authors><pubmed_authors>Wang Y</pubmed_authors><pubmed_authors>Yuan H</pubmed_authors><pubmed_authors>Su H</pubmed_authors><pubmed_authors>Zhao Z</pubmed_authors><pubmed_authors>Chen B</pubmed_authors></additional><is_claimable>false</is_claimable><name>Individualized detection of TMPRSS2-ERG fusion status in prostate cancer: a rank-based qualitative transcriptome signature.</name><description>&lt;h4>Background&lt;/h4>TMPRSS2-ERG (T2E) fusion is highly related to aggressive clinical features in prostate cancer (PC), which guides individual therapy. However, current fusion prediction tools lacked enough accuracy and biomarkers were unable to be applied to individuals across different platforms due to their quantitative nature. This study aims to identify a transcriptome signature to detect the T2E fusion status of PC at the individual level.&lt;h4>Methods&lt;/h4>Based on 272 high-throughput mRNA expression profiles from the Sboner dataset, we developed a rank-based algorithm to identify a qualitative signature to detect T2E fusion in PC. The signature was validated in 1223 samples from three external datasets (Setlur, Clarissa, and TCGA).&lt;h4>Results&lt;/h4>A signature, composed of five mRNAs co</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Feb</publication><modification>2026-05-29T10:08:20.016Z</modification><creation>2025-04-05T14:51:36.927Z</creation></dates><accession>S-EPMC10854045</accession><cross_references><pubmed>38331878</pubmed><doi>10.1186/s12957-024-03314-8</doi></cross_references></HashMap>